Dr. Nigel Stevenson from Exubrion Therapeutics® and Vivos Inc. CEO and President Dr. Mike Korenko have submitted a joint abstract entitled “Precision Radionuclide Therapy for Treating Veterinary Cancerous Tumors and Osteoarthritis” to the 11th International Conference on Isotopes on July 23-24 in Saskatoon Canada.
Nigel is Exubrion Therapeutics’ Chief Operations Officer and is also the Vivos Inc. Chief Science Advisor. The two companies co-operate since they are in totally different therapy markets. The executives of both companies decided that it is in their best interest to promote the benefits of precision radionuclide therapy.
Dr. Nigel Stevenson
Dr. Mike Korenko
Write a comment